TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02119572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual education lectures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual education lectures
Study: NCT06253520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KRAS TCR-Transduced PBL
Description: Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-C903/GRT-R904
Description: Day 0 (GRT-C903): Injection of 1.0 mL at each of 2 bilateral vaccine injections. Weeks 4, 8 and 12 (as applicable, GRT-R904): Injection of 0.25 mL of diluted GRT-R904 at each of 2 bilateral vaccine injections
Study: NCT06233461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-279 placebo-matching capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-279 placebo-matching capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-279 placebo-matching capsules.
Study: NCT02915198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For patients \< 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR \< 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo
Study: NCT06243146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Titration of Inspired Oxygen
Description: Titration of Inspired Oxygen During One-Lung Ventilation
Study: NCT05057156

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cognitive rehabilitation
Description: patients have to use an app with cognitive games

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive rehabilitation
Description: patients have to use an app with cognitive games
Study: NCT06243146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration of Inspired Oxygen
Description: Titration of Inspired Oxygen During One-Lung Ventilation
Study: NCT06635525

Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: Single-dose
Study: NCT06312332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Embolism (PE) Care in Emergency Department (ED)
Description: Utilize implementation mapping to facilitate intervention development and evaluation that can be disseminated broadly in diverse settings. Intervention to include a structured education program for clinicians on home management of patients with low-risk PE led by regional/national leaders, the development of Clinician pre-commitment, point-of-care nudge including a clinical guideline integrated into an electronic health record clinical decision support, facilitated medication access, and dedicated outpatient rapid-follow up.
Study: NCT05499364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TinCat
Description: 7-10 minute personalized video sessions based in tobacco cessation modules.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quit.gov program
Description: 7-10 minute generic videos directing participants through quit.gov program
Study: NCT05723640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1004 Injection group 1 radionuclide therapy
Description: The treatment regimen will consist of a single dose 30mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1004 Injection group 2 radionuclide therapy
Description: The treatment regimen will consist of a single dose 60mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Study: NCT06635525

Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: Single-dose

Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: Single-dose

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccine
Description: Single-dose

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccine
Description: Single-dose

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccine
Description: Single-dose
Study: NCT05805384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEDA
Description: Speech Enhancement using Dynamic thresholding Approach (SEDA) is a software algorithm that removes background noise.
Study: NCT05524051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIN816
Description: TIN816
Study: NCT05723640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1004 Injection group 3 radionuclide therapy
Description: The treatment regimen will consist of a single dose 80mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Study: NCT05524051

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05723640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1004 Injection group 4 radionuclide therapy
Description: The treatment regimen will consist of a single dose 100mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Study: NCT04810598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet
Study: NCT04596501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early and late postmenopausal women
Description: The intervention involves supervised team sports 1 h 3 x/week for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early and late postmenopausal women
Description: The intervention involves supervised team sports 1 h 3 x/week for 16 weeks.
Study: NCT05069350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% and oxubuprocaine
Description: using each drug as surface anesthesia before intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% and oxubuprocaine
Description: using each drug as surface anesthesia before intravitreal injections
Study: NCT05502770

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires
Study: NCT05516797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Description: Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring
Study: NCT05185310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation strategy during repeat AF ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation strategy during repeat AF ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation strategy during repeat AF ablation
Study: NCT05130879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRAW
Description: Sessions~1. Happiness and positivity Understanding strengths and resilience and positive attitude~2. Cognitive restructuring Identification dysfunctional automatic thoughts in problematic and emotional arousing situations Usage of cognitive -behavioural techniques to evaluate and modify dysfunctional thoughts and beliefs~3. Behavioural activation Initiation and utilization of behavioural activation techniques for positive change by increasing pleasant events Healthy interpersonal relationships Importance of peer support~4. Emotion regulation Preventing and managing conflict Emotion regulation abilities~5. Positive work climate Building supportive work environment Development of supportive collegial relationships Promotion of coworker support~6. Problem solving Problem-solving work-life problems Work-life balance Bringing it together
Study: NCT06169826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-Histidine
Description: In the outpatient setting, one chewable tablet multivitamin (Zn and folic acid containing) plus a titrated dosing of L-histidine powder or capsules starting at 2g consumed before noon escalating every 2 weeks up to 4, 6, then 8 g per day as tolerated for up to 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control
Study: NCT06133894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program PERMANENTO inspired by developmental kinesiology
Description: The intervention is based on activation of reflexive movement patterns which ensures the original reflexive control of strength, mobility and stability. After birth, we cannot control our body movements - they are reflexes hard-wired into our brains and vitally important for proper development of our body (muscular system, vestibular system, sensory system, cardiovascular system or digestive system) as well as our brain and nervous systems. During early childhood, everything becomes integrated and works perfectly according to the original design. But this design is slowly abandoned due to for example sedentary lifestyle and replaced by compensatory movement patterns that are making us weaker and defective with all the consequences that are becoming more severe as we age. The aim is restore the original design and improve posture and other crucial components of functional fitness and move better and more.
Study: NCT05845229

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-N-acylethanolamine meal
Description: Milk (150 mL), white bread (46 g), jam (10 g), cocoa powder (15 g), whole-grain cereals (30 g).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-N-acylethanolamine meal
Description: Milk (150 mL), whole-grain bread (80 g), jam (10 g), butter (5 g), instant coffee (2 g), dried apples (30 g).
Study: NCT05421182

Intervention type: OTHER
Group type: OTHER
Intervention: Revised Impact of Event Scale
Description: to measure the affect of routine life stress,everyday traumas and acute stress

Intervention type: OTHER
Group type: OTHER
Intervention: Revised Impact of Event Scale
Description: to measure the affect of routine life stress,everyday traumas and acute stress

Intervention type: OTHER
Group type: OTHER
Intervention: Hospital Anxiety and Depression scale
Description: to measure anxiety and depression

Intervention type: OTHER
Group type: OTHER
Intervention: Hospital Anxiety and Depression scale
Description: to measure anxiety and depression

Intervention type: OTHER
Group type: OTHER
Intervention: 36-Item Short Form Survey
Description: SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.

Intervention type: OTHER
Group type: OTHER
Intervention: 36-Item Short Form Survey
Description: SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.

Intervention type: OTHER
Group type: OTHER
Intervention: satisfaction survey
Description: satisfaction survey of the trusted person about the communication with ICU personal

Intervention type: OTHER
Group type: OTHER
Intervention: satisfaction survey
Description: satisfaction survey of the trusted person about the communication with ICU personal

Intervention type: OTHER
Group type: OTHER
Intervention: semi-directed interview with trusted person on the general experience of the patient's medical evacuation
Description: interview of the trusted person about the medical evacuation : evacuation announcement;organization of the medical evacuation,; concerns related to evacuations;reception and information by the center admitting the evacuated patient; arrangements of visit, patient repatriated

Intervention type: OTHER
Group type: OTHER
Intervention: semi-directed interview with trusted person on the general experience of hospitalization in intensive care
Description: interview of the trusted person about ICU hospitalization: reception in ICU; ICU organization; concerns related to ICU hospitalization, information and communication with ICU staff, arrangements of visit, context of ICU discharge
Study: NCT00917176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occipital nerve stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Occipital nerve stimulation
Study: NCT05656248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Given Intraveneously (IV)
Study: NCT06411457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811+Adebrelimab
Description: Assess the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer SHR-A1811 : 6.4mg/kg , q3w，d1, ivgtt Adebrelimab : 1200mg, q3w，d1, ivgtt
Study: NCT06042348

Intervention type: DIAGNOSTIC_TEST
Intervention: Trans abdominal ultrasound
Description: Ultra sound of the uterus and uterine blood vessels
Study: NCT06302166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Circuit training (HICT)
Description: High Intensity circuit training consisting of circuits of high intensity exercises and progressed up to 8 weeks will be provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Fasting (IF)
Description: Time restricted feeding will be used in which the intervention will begin with a 12:12 window leading to a 16:8 IF protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination of HICT and IF
Description: The participants will follow both HICT and IF for 8 weeks.
Study: NCT05656248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHA
Description: Given Intrathecal (IT)
Study: NCT06395064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimenhydrinate
Description: Dimenhydrinate 50mg intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dimenhydrinate
Description: Dimenhydrinate 50mg intravenously
Study: NCT04891809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab-Irfc 20 MG/ML [Sarclisa]
Description: Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction: 25mg\*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~\*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) \< 50 mL/min) starting dose is 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: Induction: 25mg\*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~\*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) \< 50 mL/min) starting dose is 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Induction:~Patients aged \<75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone Oral
Description: Induction:~Patients aged \<75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly
Study: NCT05656248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT
Study: NCT06336928

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05169242

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoclip
Description: In the intervention arm, one or more endoclips will be used to completely close the mucosal defect after polypectomy. Prophylactic clipping will be applied to all post-polypectomy sites. The total number of endoclips used will be recorded.
Study: NCT06571149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase or Alteplase
Description: Patients randomized to intravenous thrombolysis (IVT) treatment will receive intravenous Tenecteplase or Alteplase.
Study: NCT04458402

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated WPRT
Description: Cohort 1: 41.25 Gy in 15 fx Cohort 1: 38 Gy in 10 fx
Study: NCT05259774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relizema cram
Description: Relizema cream is a CE marked, Class IIa medical device, dermatological cream for topical use indicated for symptomatic treatment of dermatitis and erythema. Relizema cream is indicated for the treatment of itching and flushing associated with different types of dermatitis, including atopic dermatitis.
Study: NCT05369338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Light Therapy
Description: The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Controll
Description: The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it.
Study: NCT05729789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Written Exposure Therapy
Description: Group Written Exposure Therapy (GWET) is a brief cognitive behavioural therapy for PTSD aimed at allowing patients to process their traumatic experiences in a safe environment. GWET will consist of 6 group sessions (1 orientation session and 5 weekly group sessions). Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience. The written exposure will be followed by a guided discussion about the experience of writing the exposure. There is no homework assigned between sessions. However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.
Study: NCT05641805

Intervention type: OTHER
Intervention: PAQ-C (Physical activitiy questionare for children), MoCA (Montreal Cognitive Assessment), PBS (Pediatric Balance Scale), Modified Mini Mental State Examination, BMI (Body Mass Index)
Description: PAQ-C will use to evaluate physical activity level of participants. MoCA and Modified Mini Mental State Examination will use to evaluate cognitive functions of participants.~PBS will use to evaluate participants' balance responses.
Study: NCT04742361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-1007
Description: diagnostic radiopharmaceutical for PET scan
Study: NCT05905315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin
Description: Paclitaxel 175 mg/m2, followed by carboplatin 5 area under the curve (AUC). This will be administered in a 3-weekly scheme.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: According to standard treatment.